{"prompt": "['Simultaneous mRNA COVID-19 and IIV4 Vaccination Study', 'Version 2.0', 'September 17, 2021', '5.1.2', 'Third Dose mRNA COVID-19 Vaccine Schedule of Events', 'Table 7: Third Dose Schedule of Events', 'Un-', 'Procedure', 'Visit 1', 'Visit 1a', 'Visit 2', 'Visit 2a', 'Visit 3', 'Visit 4', 'Visit 5', 'Scheduled', 'Phone/Text', 'Phone/Text', 'Clinic', 'Clinic', 'Email/Data', 'Clinic', 'Email/Data', 'Clinic', 'Clinic', 'Phone', 'Review1,2,3,3', 'Review1,2,3', 'Estimated', 'Study Day', '1', '1-7', '15', '15-21', '29', '43', '121', '(Relative to Visit 1)', 'Time Following Visit 1', '0', '0-6', '14 [+/-2]', '14-20', '28 [+/-4]', '120 (+/-14)', '(Days) [Window]', 'Time Following Visit 2', '28 [+/-4]', '(Days) [Window]', 'Informed consent &', 'Medical Release of', 'X', 'Information', 'Review Eligibility Criteria', 'X', 'Review Temporary Delay', 'X', 'X', 'Criteria', 'Demographic and Health', 'X', 'History', 'Influenza and COVID-19', 'Vaccination History', 'Obtain unsolicited adverse', 'events', 'X', 'X', 'X', 'Obtain SAE and AESI', 'information', 'X', 'X', 'X', 'X', 'X', 'Concomitant medications', 'X', 'X', 'X', 'X', 'X', 'X', 'HRQOL measure', 'X', 'X', 'Measure temperature', 'X', 'X', 'X', 'Venipuncture', 'X', 'X', 'X', 'Randomization', 'X', 'Vaccination with COVID-', 'X4', '19 vaccine', 'Vaccination with IIV4 or', 'X', 'X', 'Placebo', 'Memory Aid, Link to', 'electronic symptom diary', 'X', 'X', 'given to participant', 'Assess for any immediate', 'X', 'reactogenicity symptoms', 'X', 'Electronic Diary Review\u00b2', 'X', 'X', 'Complete electronic', 'X', 'symptom diary1', 'X', '1 Symptom diary (solicited local and systemic reactogenicity events) to be completed by participant on Days 1-7 after', 'vaccination.', '2 Participants completing paper diary only will be called at days 3 [+2] and 17[+2] as a reminder and to prompt to', 'bring paper diary to next visit', '3 Electronic diary records will be reviewed by study staff at day 3, 8, 17, and 22 for completion or issues.', '4 Receipt of mRNA-1273 or BNT162b2 within 8 hours of enrollment is permitted', '35']['Simultaneous mRNA COVID-19 and IIV4 Vaccination Study', 'Version 2.0', 'September 17, 2021', 'Visit 1, Study Day 1 - Screening, Enrollment, and Vaccination (Clinic Visit)', 'Obtain written informed consent and release of medical record information', 'Obtain information on preferred method of contact for follow-up (telephone or email)', 'Review and confirm study eligibility and temporary delay criteria including pregnancy status', 'and pregnancy intention for women of childbearing potential.', 'For women of childbearing potential only, the study team can assess likelihood of', 'pregnancy based upon the following criteria if there are concerns regarding pregnancy.', 'If yes to any, can be reasonably certain not pregnant if no symptoms or signs of', 'pregnancy.', 'Is 7 days after the start of menses', 'Has not had sexual intercourse since the start of last menses', 'Has been consistently using a reliable method of contraception', 'Is < 7 days after spontaneous or induced abortion', 'Is within 4 weeks postpartum', 'Is fully or nearly fully breastfeeding (exclusively breastfeeding or the vast', 'majority [ 85%] of feeds are breastfeeds), amenorrheic and < 6 months', 'postpartum', 'Obtain demographic and medical history including history of influenza and COVID-19 vaccination', 'and reported PCR test positive COVID-19 infection', 'Obtain concomitant medication use in preceding 30 days', 'Obtain baseline HRQOL assessment', 'Obtain oral temperature', 'Obtain 10mL blood sample prior to vaccination for serologic analysis (Section 5.6.1)', 'Randomize study participant to observer-blinded IIV4 or placebo (Section 5.2.1)', 'Participant will either receive or have just received (within 8 hours) mRNA COVID-19', 'vaccine per local standard of care or mRNA COVID-19 vaccine will be administered in', 'the deltoid muscle by trained, licensed research staff.', 'Trained, licensed unblinded staff will administer study product (IIV4 or placebo) in the', 'opposite deltoid muscle in which mRNA COVID-19 vaccine was administered', 'Ensure participants receive the IIV4 Vaccine Information Sheet (VIS)30 and/or the', 'respective fact sheet for recipients and caregivers for mRNA COVID-19 vaccine during', 'visit13,32', 'Dispense paper memory aid (if subject selects paper), thermometer, and ruler (in order to', 'standardize measurements). Review instructions for use of thermometer, ruler, and', 'electronic memory aid completion.', 'Observe participant for a minimum of 30 minutes and assess for any immediate', 'reactogenicity symptoms', 'Confirm date of next appointment', 'Visit 1a, Study Days 1 - 7 Post Visit 1', 'Participants complete electronic or paper solicited symptom diary and HRQOL', 'assessment at approximately the same time each day for days 1-7', 'Participants using paper diary:', 'Study staff will call participants on day 3 post Visit 1 as a reminder to fill out the', 'symptom diary and HRQOL assessments on day 1-7 post Visit 1 regarding', 'reactogenicity events and to bring the diary card to the next visit.', 'Participants will be:', '36']\n\n###\n\n", "completion": "END"}